<DOC>
	<DOC>NCT01577537</DOC>
	<brief_summary>The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV). After screening eligible participants will be randomized to receive either 1% SPL7013 Gel or hydroxyethyl cellulose (HEC) placebo gel at a dose of 5g administered vaginally at bedtime for 7 consecutive days. Participants will be assessed for BV (both by Amsel criteria and Nugent score) at screening/Baseline, after last application (End of Treatment, EOT, Day 9-12) and at the final study visit approximately 2-3 weeks after last dose (Test of Cure, TOC, Day 21-30).</brief_summary>
	<brief_title>A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<criteria>Key eligibility criteria: Postmenarchal females, aged 12 years or more Diagnosis of BV by Amsel criteria (ie all four of the following signs/symptoms: presence of white to grey homogeneous discharge; positive whiff test indicating an amine (fishy) odor with addition of potassium hydroxide; vaginal pH greater than 4.5; and presence at least 20% clue cells of total epithelial cells Nugent score of at least 4 Otherwise healthy, as determined by medical history, physical examination normal Pap smear at or documented within 24 months of screening</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>SPL7013</keyword>
	<keyword>VivaGel</keyword>
	<keyword>bacterial vaginosis</keyword>
	<keyword>BV</keyword>
</DOC>